Humana’s CenterWell Pharmacy will distribute Eli Lilly obesity medications under a new program targeting employers, according to a Jan. 12 news release. The pharmacy will serve those in employer plan-sponsored carve-out programs. Humana Pharmacy Segment President Bethanie Stein, PharmD, said there is…
GLP-1s
Ochsner Connected Health, part of New Orleans-based Ochsner Health, has partnered with Crux to expand access to affordable obesity care through a new employer benefits platform. Under the agreement, Ochsner will serve as the first cardiometabolic care provider on Crux’s…
The first FDA-approved oral GLP-1 for weight loss is now available to U.S. patients for $299 per month through a self-pay platform. Self-paying patients can order the Wegovy pill at $149 per month as they work up to the two…
A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect on an individual’s risk of developing obesity-related cancers. The study, published Dec. 9 in Annals…
Wegovy and Zepbound, two popular weight loss GLP-1 medications, would remain cost-effective at a higher price, according to an Oct. 29 revised report from the Institute for Clinical and Economic Review. The estimated annual net price for Eli Lilly’s Zepbound…
Advertisement
In October, GLP-1 manufacturers inked partnerships with big-box retailers to increase access as several studies indicate a low adherence rate for the expensive medications. Three updates on the GLP-1 drug class: 1. Prescriptions go unfilled Despite expanded approvals for conditions…
As of Oct. 17, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications. The approved indications for brand-name GLP-1s: Bydureon (exenatide) Type 2 diabetes in patients ages 10…
GLP-1 medications, originally approved for diabetes, are rapidly expanding into new therapeutic territory — from cardiovascular to anti-inflammatory effects. Norma Keller, MD, chief of cardiology at NYC Health + Hospitals/Bellevue, recently told Becker’s prevention programs should embrace these therapies. “We…
A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective option to treat obesity. The findings mark a shift…
Eli Lilly’s experimental oral GLP-1 medication, orforglipron, led to an average weight loss of 12.4%, or 27.3 pounds, in a phase 3 trial involving more than 3,000 adults. Based on the results, the drugmaker said Aug. 7 it plans to…